Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Infante, MS; Salmanton-García, J; Fernández-Cruz, A; Marchesi, F; Jaksic, O; Weinbergerová, B; Besson, C; Duarte, RF; Itri, F; Valković, T; Szotkovski, T; Busca, A; Guidetti, A; Glenthøj, A; Collins, GP; Bonuomo, V; Sili, U; Seval, GC; Machado, M; Cordoba, R; Blennow, O; Abu-Zeinah, G; Lamure, S; Kulasekararaj, A; Falces-Romero, I; Cattaneo, C; Van, Doesum, J; Piukovics, K; Omrani, AS; Magliano, G; Ledoux, MP; de, Ramon, C; Cabirta, A; Verga, L; López-García, A; Da, Silva, MG; Stojanoski, Z; Meers, S; Lahmer, T; Martín-Pérez, S; Dávila-Vals, J; Van, Praet, J; Samarkos, M; Bilgin, YM; Karlsson, LK; Batinić, J; Nordlander, A; Schönlein, M; Hoenigl, M; Ráčil, Z; Mladenović, M; Hanakova, M; Zambrotta, GPM; De, Jonge, N; Adžić-Vukičević, T; Nunes-Rodrigues, R; Prezioso, L; Navrátil, M; Marchetti, M; Cuccaro, A; Calbacho, M; Giordano, A; Cornely, OA; Hernández-Rivas, JÁ; Pagano, L.
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Front Oncol. 2022; 12: 992137 Doi: 10.3389/fonc.2022.992137 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Hönigl Martin
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.

Find related publications in this database (Keywords)
SARS-CoV-2
targeted drugs
infection risk
immune system COVID19
lymphoproliferative diseases (LPD)
chronic lymphocytic leukemia (CLL)
non-Hodgkin lymphoma (NHL)
© Med Uni Graz • Impressum